Simplify Logo

Internship

Intern – MBA Finance Program

2025

Confirmed live in the last 24 hours

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Princeton, NJ, USA

Onsite presence is essential for collaboration and productivity.

US Citizenship Required

Category
Corporate Finance
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Financial analysis
Marketing
Excel/Numbers/Sheets
Requirements
  • Candidates should expect to receive a Masters in Business Administration degree during the following school year, scheduled to graduate by the Spring of 2026.
  • The ideal candidate will have 3 to 5 years’ work experience and strong intellectual, financial and analytical skills with demonstrated ability for quickly grasping new and complex concepts.
  • Strong interpersonal skills, including the ability to influence others and work effectively in a matrix organization, are essential.
  • Leadership potential is highly valued, and a commitment to integrity, professionalism and teamwork is required.
  • Successful candidates will also demonstrate superior financial modeling skills, specifically in Excel, and the ability to quickly learn financial/accounting software.
  • Candidates must be a US citizen, have a lawful permanent resident of the US or otherwise authorized to work in the US without requiring sponsorship now or in the future.
Responsibilities
  • Assignments include but are not limited to: development of operating budgets, R&D portfolio allocation, financial forecasting for compounds in development, financial analysis of operating performance and return on capital expenditures.
  • Associates also have the opportunity to work on a specific brand where they team up with marketing to manage the brand P&L and develop strategic initiatives for growing the business.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are then sold after receiving regulatory approval. BMS also produces generic drugs, providing affordable alternatives that maintain the same quality and safety standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while adhering to sustainability and corporate responsibility principles.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's involvement in Nobel Prize-winning immunology research underscores its leadership in groundbreaking scientific advancements.
  • The robust pipeline of molecular glues and other innovative therapies promises significant revenue growth and market expansion.
  • Recognition in the Dow Jones Sustainability Index North America highlights BMS's commitment to corporate responsibility and sustainability, enhancing its reputation and stakeholder trust.

What critics are saying

  • The termination of strategic collaborations, such as with Eisai, could impact BMS's ability to bring new therapies to market efficiently.
  • Ongoing layoffs and restructuring efforts may lead to decreased employee morale and potential disruptions in operations.

What makes Bristol-Myers Squibb unique

  • Bristol Myers Squibb's dual focus on innovative and generic medicines allows it to cater to a broad spectrum of healthcare needs, unlike competitors who may focus solely on one area.
  • Their commitment to sustainability and ESG goals sets them apart in the biopharmaceutical industry, appealing to socially conscious investors and stakeholders.
  • BMS's extensive R&D investment in oncology, immunology, and cardiovascular diseases positions it as a leader in developing cutting-edge treatments for serious diseases.